- TREOS Bio has initiated **OBERTO-202**, a potentially registration-enabling Phase II clinical trial, through collaboration agreements with Charité – Universitätsmedizin Berlin and Junshi Biosciences.  **[1863127_935dbe8635664a13a292f5b8c9892061_0]** 
- The trial will evaluate **PolyPEPI1018**, TREOS Bio's lead immunotherapy, combined with toripalimab and standard of care, in approximately **140 patients** with relapsed/refractory **microsatellite stable (MSS) metastatic colorectal cancer (CRC)**.  **[1863127_935dbe8635664a13a292f5b8c9892061_0]** 
- MSS CRC represents approximately **85%** of all colorectal cancer cases, affecting an estimated **130,000** new patients annually in the US, and is a population where current immunotherapies have shown limited efficacy.  **[1863127_935dbe8635664a13a292f5b8c9892061_0]** 
- The company also completed a **$2.1 million** bridge financing from existing investors, increasing total financing raised to date to **$47 million**.  **[1863127_935dbe8635664a13a292f5b8c9892061_0]**

Tyra Biosciences (TYRA)